Glaxo Wellcome withdraws irritable bowel syndrome medication.
D002243:Carbolines / Q000009:adverse effects*; D017091:Colitis, Ischemic / Q000139:chemically induced; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D004335:Drug and Narcotic Control; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron